Alzheimer’s Disease (AD) – Epidemiology Insights and Forecast Report – 2020 To 2040

 Alzheimer’s Disease (AD) Epidemiology Insights

Thelansis’s “Alzheimer’s Disease (AD) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Alzheimer’s Disease (AD) Overview

Alzheimer’s disease (AD) is the foremost cause of dementia, accounting for approximately 60% to 80% of all cases of dementia. This condition is a progressive and neurodegenerative ailment characterized by three principal features within the brain: Amyloid plaques, anomalous clumps formed from proteins, remnants of neurons, and fragments of other nerve cells. Neurofibrillary tangles (NETs), knotted bundles of fibers containing clusters of a protein known as tau, are situated within neurons. The deterioration of connections between neurons leads to memory and learning deficits. Alzheimer’s disease exhibits distinctive brain alterations (pathology) distinct from those of other causes of dementia, such as Lewy body disease or Cerebrovascular disease. When these coexisting pathologies are identified during a person’s lifetime, it is called mixed dementia.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
• Global findings
• G8 findings
• Regional findings
• Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

Read more:  Alzheimer’s Disease (AD) – Epidemiology Insights and Forecast Report – 2020 To 2040